Emanuela Sant’Antonio

Author

Also Known As

E Sant'Antonio, E Sant’Antonio, E. Sant'Antonio, E. Sant’Antonio, Emanuela Sant'Antonio, Emanuela Sant'antonio, Emanuela Sant’Antonio, Emanuela Sant’antonio, Emmanuela Sant'Antonio, Virginia V. Ferretti

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

University of Pavia Istituti di Ricovero e Cura a Carattere Scientifico University of Florence Policlinico San Matteo Fondazione University of Siena

About

Emanuela Sant’Antonio is an author at University of Pavia specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	212
2	Pathology	2	2	123
3	Epidemiology	1	1	56
4	Immunology	1	1	56
5	Pharmacology	1	1	89

Emanuela Sant’Antonio

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan, New England Journal of Medicine	2013	1.9K
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes Elisa Rumi, Daniela Pietra, Virginia Valeria Ferretti, Blood	2013	572
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis Elisa Rumi, Daniela Pietra, Cristiana Pascutto, Blood	2014	380
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms Daniela Pietra, Elisa Rumi, Virginia Valeria Ferretti, Leukemia	2015	275
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group Giada Rotunno, Annalisa Pacilli, Valentina Artusi, American Journal of Hematology	2016	93
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms Elisa Rumi, Daniela Pietra, Paola Guglielmelli, Blood	2013	92
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists Valerio De Stefano, Marco Ruggeri, Francisco Cervantes, Leukemia Vitamin K AntagonistsThrombosisThrombopoiesisVenous ThrombosisCardiovascular Disease	2016	89
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features Giacomo Coltro, Giada Rotunno, Lara Mannelli, Blood Advances	2020	76
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra, Blood	2014	71
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases Emanuela Sant’Antonio, Paola Guglielmelli, Lisa Pieri, American Journal of Hematology Retrospective StudyThrombosisHematological MalignancyVenous ThrombosisSplanchnic Vein Thromboses	2019	67

Page 1